Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004919 · ClinicalTrials.gov registry record · Phase 1
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
A Phase 1 study of Unspecified Childhood Solid Tumor, Protocol Specific, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00004919 is a Phase 1 study of Unspecified Childhood Solid Tumor, Protocol Specific that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants, below the 1,635-participant average among 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00004919, a Phase 1 study of Unspecified Childhood Solid Tumor, Protocol Specific, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. Phase I trial to study the effectiveness of irinotecan and cisplatin with or without amifostine in treating children who have solid tumors that have not responded to previous therapy.
Conditions Studied
Interventions
- DRUG cisplatin
- OTHER pharmacological study
- DRUG irinotecan hydrochloride
- DRUG amifostine trihydrate
Study Locations (1)
California
- COG Phase I Consortium - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004919
The ClinicalTrials.gov registry entry for NCT00004919 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,635-participant average among 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials with a reported enrollment target (98% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unspecified Childhood Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.
NCT00004919 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00004919 about?
NCT00004919 is a clinical study titled "Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy". Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. Phase I trial to study the effectiveness of irinotecan and cisplatin with or without a...
What is the current status of trial NCT00004919?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1999-12.
What conditions does trial NCT00004919 study?
This clinical trial studies the following conditions: Unspecified Childhood Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00004919?
The interventions under investigation include: cisplatin (DRUG), pharmacological study (OTHER), irinotecan hydrochloride (DRUG), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00004919?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004919 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Childhood Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
COMPLETED · Phase 1
-
Bevacizumab in Treating Young Patients With Refractory Solid Tumors
COMPLETED · Phase 1
-
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
COMPLETED · Phase 1
-
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
COMPLETED · Phase 1
-
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
COMPLETED · Phase 1
-
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.